Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on December 21, 2017. The registrant is a Delaware corporation headquartered in San Diego, California. Note: The request metadata lists "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as "Trovagene, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial results.
Material Changes
The primary material event reported is the activation of the second clinical trial site for the Company's Phase 1b/2 multicenter trial of PCM-075 in patients with Acute Myeloid Leukemia (AML). The new site is the Virginia Piper Cancer Institute, with Dr. Michaela Tsai serving as the Principal Investigator.
Outlook and Management Commentary
Management announced the expansion of clinical operations via a press release dated December 21, 2017. The filing does not contain specific financial guidance, risk factor updates, or discussion of contingencies beyond the clinical trial progress.
Investor Verification Checklist
- Verify the correct registrant name (Trovagene, Inc. vs. Cardiff Oncology, Inc.) in the context of the investment thesis.
- Confirm the status and enrollment progress of the PCM-075 Phase 1b/2 trial at the Virginia Piper Cancer Institute.
- Review the full text of the press release (Exhibit 99.1) for additional details on the trial design and patient eligibility.
- Check subsequent filings for financial updates, as this 8-K contains no financial data.